{"title": "GSK stays a step ahead in RSV vaccine battle as Arexvy becomes available at US pharmacies", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/pharma/gsk-stays-step-ahead-rsv-battle-arexvy-becomes-available-us", "hostname": "fiercepharma.com", "description": "As companies have flocked to compete in the new respiratory syncytial virus (RSV) vaccine market, GSK has had the best timing. | As companies have flocked to compete in the new respiratory syncytial virus (RSV) vaccine market, GSK has had the best timing. In May, the U.K. company was first to secure FDA approval for its shot Arexvy for adults 60 and older, beating out rivals from Pfizer and Moderna. And now\u2014well in advance of the fall and winter RSV season\u2014Arexvy is available in major U.S. retail pharmacies, the company said.", "sitename": "FiercePharma", "date": "2023-08-17", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}